Belgian molecular diagnostics firm Multiplicom said this week that it has been awarded €200,000 ($250,000) from the Flemish agency for Innovation by Science and Technology to develop a blood-based non-invasive molecular diagnostic test for fetal aneuploidy.

The test would use the same multiplexed endpoint PCR- and sequencing-based workflow as the other tests in Multiplicom's portfolio, including research-use-only diagnostic kits for breast cancer, colon cancer, and cystic fibrosis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.